AstraZeneca and Imperial spin-off VaxEquity enter into saRNA partnership
AstraZeneca has signed a collaboration deal with VaxEquity, a spin-off of Imperial College London, for discovering, developing, and commercializing the latter’s self-amplifying RNA (saRNA) therapeutics platform. The long-term research collaboration is aimed at optimizing and validating the saRNA platform of VaxEquity to use it for advancing novel therapeutic programs. AstraZeneca will support the Imperial College […]